+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 800 Actively Recruiting clinical trials

S

Actively Recruiting

Knee osteoarthritis OA is a common degenerative and inflammatory joint disease causing pain and limited mobility, affecting millions worldwide. This research evaluates the clinical results of treating patients with knee OA and chronic pain that has not improved after at least three months of conventional conservative therapy. The study focuses on selective arterial embolization as a treatment option for patients who are not candidates for or refuse surgery and suffer from refractory chronic pain. The treatment involves transarterial microembolization, which selectively targets and blocks blood vessels causing inflammation in the knee. This procedure uses micro-catheters to inject embolizing material into pathological genicular arterial branches, followed by diagnostic arteriography to confirm successful embolization. The study includes 43 patients who will undergo this procedure after providing informed consent. Patients will be followed up with clinical evaluations at 1, 3, 6, 12, and 24 months after treatment or until they drop out for other reasons. Participants will be involved in regular clinical assessments to monitor pain levels using the Visual Analog Scale VAS and other measures like quality of life SF-36, joint function WOMAC score, range of motion, and overall treatment assessment over two years. Researchers will also measure bilateral knee circumferences to evaluate changes. The study aims to understand the treatments impact on pain reduction and joint function over time, with ongoing safety and progress monitoring throughout the follow-up period.

Age: 40Years +All Genders
1 location
E

Actively Recruiting

Researchers are evaluating CGT9486 bezuclastinib in an open-label Phase 2 study for patients with Advanced Systemic Mastocytosis AdvSM, including Aggressive Systemic Mastocytosis ASM, Systemic Mastocytosis with an Associated Hematologic Neoplasm SM-AHN, and Mast Cell Leukemia MCL. The study aims to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of bezuclastinib as a single agent in these conditions. Participants receive bezuclastinib tablets orally, taken continuously in 28-day cycles. The study has two parts Part I focuses on identifying clinically active and tolerable doses of bezuclastinib, while Part II determines the drugs efficacy by measuring the modified IWG Objective Response Rate ORR and confirming the exposure-response relationship. Treatment and evaluation continue for up to 18 months. During the study, participants undergo assessments including laboratory tests, imaging to measure spleen and liver volume, and evaluation of mutation allele burden, serum tryptase, and histopathologic changes in blood and bone marrow. Safety is monitored through adverse event reporting. The study measures duration and time to response, progression-free survival, and overall survival. Participants are involved in regular monitoring throughout the treatment period extending up to 18 months.

Age: 18Years +All GendersPhase 2
42 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.

Age: 18Years +All GendersPhase 2Phase 3
88 locations
P

Actively Recruiting

Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.

Age: 18Years +All GendersPhase 3
126 locations
I

Actively Recruiting

Researchers are creating a national registry in Italy to observe and record how multiple myeloma is diagnosed and treated in routine clinical practice. This observational study aims to describe the standard care for patients with multiple myeloma across different hematology centers, reflecting the current situation and variations in treatment and patient characteristics. Both retrospective and prospective data will be collected to provide a comprehensive view. The study involves a non-interventional, multicenter registry that includes patients diagnosed with multiple myeloma since January 1, 2019. Patients are enrolled consecutively during their routine appointments, and data are collected using an electronic platform. Patients participating in other studies may also be included, with baseline and survival data collected during their participation in interventional trials. Hospital visits for data collection occur approximately every six months. Participants will be followed for up to three years, during which researchers will measure overall survival and time to next treatment. Patient-reported outcomes and costs incurred by patients will also be tracked over this period. The study encourages patient involvement and aims to enhance understanding of multiple myeloma care in Italy without altering standard treatment or requiring additional interventions.

Age: 18Years +All Genders
27 locations
E

Actively Recruiting

Researchers are investigating new treatments for advanced renal cell carcinoma RCC, a type of kidney cancer. This study compares a standard targeted therapy called belzutifan with a combination of belzutifan and another targeted therapy, zanzalintinib. The goal is to find out if adding zanzalintinib helps people with advanced RCC live longer and without their cancer worsening compared to belzutifan alone. Participants will be randomly assigned to one of two groups. One group will take 120 mg of belzutifan orally plus 60 mg of zanzalintinib once daily for about 24 months. The other group will take 120 mg of belzutifan plus a placebo matching zanzalintinib once daily for the same period. Both treatments are given as tablets taken by mouth. During the study, participants will have regular evaluations to monitor their cancers status, side effects, and quality of life. Researchers will use specific measures such as progression-free survival PFS and overall survival OS over up to 50 months. Other assessments include tumor response, duration of response, adverse events, and changes in health questionnaires related to physical function and symptoms. Safety and treatment effects will be carefully tracked throughout the study.

Age: 18Years +All GendersPhase 3
106 locations
P

Actively Recruiting

Researchers are investigating new treatments for advanced renal cell carcinoma RCC that has returned after prior therapy. The study aims to find out if the combination of belzutifan and zanzalintinib can help people with recurrent advanced RCC live longer without their cancer worsening compared to the drug cabozantinib. This is a phase 3 randomized trial evaluating these treatments in participants who have experienced recurrence during or after prior anti-PD-1L1 therapy. Participants are randomly assigned to receive either belzutifan plus zanzalintinib taken orally once daily or cabozantinib taken orally once daily. They continue their assigned treatment until certain reasons require stopping the study intervention. The study compares the effects of these treatments on cancer progression and survival among people with advanced RCC who have had disease recurrence after adjuvant therapy. During the study, participants will be regularly monitored for progression-free survival and overall survival for up to about 73 months. Researchers will also assess tumor response, duration of response, adverse events, and quality of life using questionnaires over approximately 25 months. The study involves ongoing evaluations to understand how these treatments affect symptoms, functioning, and overall health during long-term follow-up.

Age: 18Years +All GendersPhase 3
127 locations
E

Actively Recruiting

Researchers are exploring a new treatment for chronic myeloid leukemia CML, a type of blood cancer. The study aims to evaluate the safety and tolerability of different doses of MK-4208 Tern-701 and to identify the highest dose that participants can tolerate and that may be effective in treating CML. This trial is being conducted in phases 1 and 2 to gather important information about MK-4208s use in this disease. Participants will receive MK-4208 orally at various doses ranging from 160 mg to 500 mg, taken once or twice daily depending on the study part. The study includes multiple groups that receive different doses to compare safety and tolerability. Treatment duration and dosing schedules may vary across the study parts, with careful monitoring of participants during the intervention. Throughout the study, participants will undergo regular assessments including monitoring for dose-limiting toxicities, adverse events, and serious side effects up to three years. Researchers will also track hematologic and molecular responses to the treatment and measure drug levels in the blood over time. Safety, tolerability, and efficacy data will be collected to better understand the potential role of MK-4208 in treating CML, with the study expected to last until 2030 for complete follow-up.

Age: 18Years +All GendersPhase 1Phase 2
54 locations
S

Actively Recruiting

Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.

Age: 18Years +All GendersPhase 3
227 locations
P

Actively Recruiting

Researchers are investigating the effects of an experimental drug called BNT323 also known as DB-1303 compared with standard chemotherapy in women with recurrent endometrial cancer that expresses the HER2 protein. This Phase III study includes two groups based on HER2 levels one group with lower HER2 expression 1 or 2 who have previously received immune checkpoint inhibitors, and another with higher HER2 expression 3. The study aims to evaluate how well these treatments control the cancer and their safety profiles. Participants in Cohort 1 will be randomly assigned to receive either BNT323 or a chemotherapy drug chosen by their doctor, such as doxorubicin or paclitaxel or docetaxel if paclitaxel is unsuitable. Cohort 2 participants will receive BNT323 alone. Treatments are given through intravenous infusions and continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. The study includes screening, treatment lasting about six months, and long-term follow-up for up to 53 months to monitor survival and other outcomes. During the trial, participants will undergo various assessments including imaging scans to measure tumor size, evaluations of side effects, blood tests to study drug behavior and immune responses, and quality of life questionnaires. Safety follow-up occurs shortly after treatment ends, followed by extended monitoring for treatment effectiveness and survival. Participants are closely observed throughout to understand how well BNT323 works compared to chemotherapy and its impact on health and wellbeing.

Age: 18Years +FEMALEPhase 3
206 locations

1-10 of 800

1